The Determination and Comparative Study of Basic Hormonal Assessment in Polycystic Ovary Syndrome (PCOS) Women Undergoing Assisted Reproduction Treatment in Southern Part of Nigeria


  • Ngozi O. Ibadin Department of Microbiology, University of Benin, Benin City Nigeria
  • Rachael O Okojie Department of Microbiology, University of Benin, Benin City Nigeria
  • Kennedy O Ibadin Human Reproduction Research Program Department of Obstetrics and Gynecology University of Benin Teaching Hospital Benin City Nigeria


Polycystic Ovarian Syndrome (PCOS) is a heterogenous disorder frequently diagnosed in women attending fertility clinics in Nigeria. it is characterized by anovulation, hyper androgenism and polycystic ovary, several factors have been associated with the pathophysiology of this disorder.A prospective cross-sectional study was conducted in four selected fertility clinics in South-South part of Nigeria. The purposive sampling technique was used to recruit participants. A total of 206 women were recruited in this study, 101 (49.1%) women fulfilled the Rotterdam criteria for the diagnosis of PCOS, while 105 women (50.9%) without PCOS were included as control. Biochemical hyper-androgenism as described by the Rotterdam criteria was observed in 69(68%) of women with PCOS, Elevated Anti-mullerian hormone (AMH) 87(86%) and elevated Luteinizing hormone (LH) 76(75%) were observed in women with PCOS.The aim of the study was to Determine and Compare levels of Luteinizing Hormone (LH) Follicle Stimulating Hormone (FSH) Anti-mullerian Hormone (AMH) Testosterone in the follicular fluid of women with PCOS undergoing Assisted Reproduction Treatment.


. A. Gougeon. “Dynamics of follicular growth in the human: a model from preliminary results.” Hum Reprod. vol 1: pp 81-77, 1986.

. J G. Thompson, M. Lane, R.B. Gilchrist.” Metabolism of the bovine cumulus-oocyte complex and influence on subsequent developmental competence.” Soc Reprod Fertil Suppl, vol. 64, pp 179-190, 2007.

. R.B Gilchrist, J.G. Thompson. “Oocyte maturation: emerging concepts and technologies to improve developmental potential in vitro.” Theriogenology, vol. 67, pp 6-15, Jan 2007.

. J.A. Visser, F.H. de Jong, J.S. Laven and A.P. Themmen. “Anti-Mullerian hormone: a new marker for ovarian function.” Reproduction, vol. 131, pp 1-9 2006.

. A.L. Durlinger, B. Kramer, F.H. de Jong, J.T. Uilenbroek, J.A. Grootegoed et al. “Control of primordial follicle recruitment by anti-mullerian hormone in the mouse ovary.” Endocrinology vol. 140, pp 5789-5796, 2009.

. J.A. Visser, A.L. Durlinger, I.J. Peters, E.R. van den Heuvel, U.M. Rose, P. Kramer, F.H. de Jong and A.P. Themmen. “Increased oocyte degeneration and follicular atresia during the estrous cycle in anti-Mullerian hormone null mice.” Endocrinology, vol. 148, pp. 2301-2308, 2007.

. M.P. Grossman, S.T. Nakajima, M.E. Fallat and Y. Sioy. “Mullerian-inhabiting substance inhibits cytochrome P450 aromatase activity in human granulosa lutein cell culture.” Fertility and Sterility, vol. 89, pp. 1364-1370, 2008.

. L.C. Varanasi, A. Subasinghe, Y.L Jayasinghe, E.T. Callegari, S.M. Garland, A. Gorelik, J.D. Wark. “Polycystic ovarian syndrome: Prevalence and impact on the wellbeing of Australian women aged 16-29 years.” Aust N Z J Obstet Gynaecol. 2018 Apr; vol. 58 issue 2, pp. 222-233, 2018.

. R. Pasquali, A. Gambineri, U. Pagotto. “The impact of obesity on reproduction in women with polycystic ovary syndrome.” BJOG, vol. 113, pp. 1148-1159, Oct 2006.

. P. Pigny, E. Merlen, Y. Robert, C. Cortet-Rudelli, C. Decanter, S. Jonard, D. Dewailly. “Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest.” J Clin Endocrinol Metab. 2003 Dec vol. 88, pp 5957-5962, Dec 2003.

. Robin Geoffroy, Marie Deknuydt, Anne-Laure Barbotin, Pascal Pigny, Sophie Catteau-Jonard, Didier Dewailly. “Anti-Müllerian hormone as a driving force of polycystic ovary syndrome, independently from insulin resistance.” Reproductive Biomedicine Online, Vol 42, issue 5, pp 1023-1031, 2021.

. A.J. Jakimiuk, S.R. Weitsman, A. Navab, D.A. Magoffin. “Luteinizing hormone receptor, steroidogenesis acute regulatory protein, and steroidogenic enzyme messenger ribonucleic acids are overexpressed in thecal and granulosa cells from polycystic ovaries.” J Clin Endocrinol Metab, vol. 86, pp. 1318-1323, Mar 2001.

. S.L. Mumford, R.S. Legro, M.P. Diamond, C. Coutifaris, A.Z. Steiner, W.D Schlaff, R. Alvero, G.M. Christman, P.R. Casson, H. Huang, N. Santoro, E. Eisenberg, H. Zhang, M.I. Cedars. “Baseline AMH Level Associated With Ovulation Following Ovulation Induction in Women With Polycystic Ovary Syndrome.” J Clin Endocrinol Metab, vol. 101, pp. 3288-3296, Sep. 2016.

. A. Pierre, M. Peigné, M. Grynberg, N. Arouche, J. Taieb, L. Hesters, J. Gonzalès, J.Y. Picard, D. Dewailly, R. Fanchin, S. Catteau-Jonard, N. di Clemente. “Loss of LH-induced down-regulation of anti-Müllerian hormone receptor expression may contribute to anovulation in women with polycystic ovary syndrome.” Hum Reprod, vol. 28, pp. 762-769, Mar. 2013.

. R. Deswal, N. Sanda, A.S. Dang. “Association of Luteinizing hormone and LH receptor gene polymorphism with susceptibility of Polycystic ovary syndrome.” Syst Biol Reprod Med, vol. 65, pp. 400-408, Oct. 2013.

. S. Catteau-Jonard, P. Pigny, A.C. Reyss, C. Decanter, E. Poncelet and D. Dewailly. “Changes in serum anti-Mullerian hormone level during low-dose recombination follicular stimulating hormone therapy for anovulation in polycystic ovary syndrome.” Journal of Clinical Endocrinology and Metabolism vol. 92, pp. 4138-4143, 2007.




How to Cite

Ngozi O. Ibadin, Rachael O Okojie, & Kennedy O Ibadin. (2023). The Determination and Comparative Study of Basic Hormonal Assessment in Polycystic Ovary Syndrome (PCOS) Women Undergoing Assisted Reproduction Treatment in Southern Part of Nigeria. International Journal of Sciences: Basic and Applied Research (IJSBAR), 72(1), 53–61. Retrieved from